These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 12540202)
1. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists. Haga JH; Jennings LK; Slack SM Ann Biomed Eng; 2002; 30(10):1262-72. PubMed ID: 12540202 [TBL] [Abstract][Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
3. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. Moser M; Bertram U; Peter K; Bode C; Ruef J J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060 [TBL] [Abstract][Full Text] [Related]
4. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046 [TBL] [Abstract][Full Text] [Related]
5. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Marciniak SJ; Jordan RE; Mascelli MA Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828 [TBL] [Abstract][Full Text] [Related]
6. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates. Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146 [TBL] [Abstract][Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Leclerc JR Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256 [TBL] [Abstract][Full Text] [Related]
8. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996 [TBL] [Abstract][Full Text] [Related]
9. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond. Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157 [TBL] [Abstract][Full Text] [Related]
10. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Frelinger AL; Furman MI; Barnard MR; Krueger LA; Dae MW; Michelson AD Am J Cardiol; 2003 Nov; 92(9):1099-101. PubMed ID: 14583364 [TBL] [Abstract][Full Text] [Related]
11. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761 [TBL] [Abstract][Full Text] [Related]